<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006007.pub4" GROUP_ID="LIVER" ID="468204081311513293" MERGED_FROM="" MODIFIED="2015-06-08 14:01:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="03" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.2">
<COVER_SHEET MODIFIED="2015-06-08 13:59:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-06-07 23:04:38 +0200" MODIFIED_BY="Anne Lawson">Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease</TITLE>
<CONTACT>
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-06-08 13:59:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Arturo</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Martí-Carvajal</LAST_NAME>
<SUFFIX>MD, MSc</SUFFIX>
<POSITION/>
<EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Iberoamerican Cochrane Network</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Valencia</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12177" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Ivan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Solà</LAST_NAME>
<SUFFIX/>
<POSITION>Researcher</POSITION>
<EMAIL_1>isola@santpau.cat</EMAIL_1>
<EMAIL_2>ensayos@cochrane.es</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau)</DEPARTMENT>
<ORGANISATION>CIBER Epidemiología y Salud Pública (CIBERESP)</ORGANISATION>
<ADDRESS_1>Sant Antoni Maria Claret 171 - Edifici Casa de Convalescència</ADDRESS_1>
<ADDRESS_2/>
<CITY>Barcelona</CITY>
<ZIP>08041</ZIP>
<REGION>Catalunya</REGION>
<COUNTRY CODE="ES">Spain</COUNTRY>
<PHONE_1>+34 932 919 527</PHONE_1>
<PHONE_2/>
<FAX_1>+34 932 919 525</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-06-08 13:59:45 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="17" MONTH="3" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="26" MONTH="2" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="27" MONTH="2" YEAR="2020"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="6" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-03-26 11:58:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-03-26 11:16:59 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="26" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>Searches performed in February 2015; however, there were still no trials on the subject of our review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-03-26 11:58:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="26" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>No change in conclusion. Randomised clinical trials are still lacking.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-03-26 11:42:50 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
<SOURCES_OF_SUPPORT MODIFIED="2009-01-08 21:43:35 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-01-08 21:43:35 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-01-08 21:42:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>Iberoamerican Cochrane Center</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2009-01-08 21:43:35 +0100" MODIFIED_BY="[Empty name]">
<NAME>Cochrane Hepato-Biliary Group</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION>
<P>Academic</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-06-08 13:31:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2015-06-08 11:00:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2015-06-08 11:00:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">Antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease</TITLE>
<SUMMARY_BODY MODIFIED="2015-06-08 11:00:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>
<B>Review question</B>
<BR/>We reviewed antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
<P>
<B>Background</B>
</P>
<P>Upper gastrointestinal bleeding (vomiting of blood) is one of the most frequent causes of illness and death in the course of liver disease. People with liver disease frequently have haemostatic abnormalities, which include hyperfibrinolysis (increased prevention of blood clotting). Antifibrinolytic amino acids have been suggested for the treatment of gastrointestinal emergency, but it is unknown whether they are of benefit or cause harm when used for treating upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We found no randomised clinical trials (studies where people are randomly put into one of two or more treatment groups) for inclusion in this updated review on the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with liver diseases. The evidence is current to February 2015.</P>
<P>
<B>Key results</B>
</P>
<P>Accordingly, we cannot recommend or refute antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
<P>
<B>Quality of evidence</B>
</P>
<P>We found no randomised clinical trials.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-06-08 12:44:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ABS_BACKGROUND MODIFIED="2015-06-08 10:58:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Upper gastrointestinal bleeding is one of the most frequent causes of morbidity and mortality in the course of liver cirrhosis. People with liver disease frequently have haemostatic abnormalities such as hyperfibrinolysis. Therefore, antifibrinolytic amino acids have been proposed to be used as supplementary interventions alongside any of the primary treatments for upper gastrointestinal bleeding in people with liver diseases. This is an update of this Cochrane review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-06-08 10:58:49 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-06-08 12:44:27 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Controlled Trials Register (February 2015), Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2 of 12, 2015), MEDLINE (Ovid SP) (1946 to February 2015), EMBASE (Ovid SP) (1974 to February 2015), Science Citation Index EXPANDED (1900 to February 2015), LILACS (1982 to February 2015), World Health Organization Clinical Trials Search Portal (accessed 26 February 2015), and the metaRegister of Controlled Trials (accessed 26 February 2015). We scrutinised the reference lists of the retrieved publications.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-07-25 13:31:33 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trials irrespective of blinding, language, or publication status for assessment of benefits and harms. Observational studies for assessment of harms.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-06-08 10:59:16 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to summarise data from randomised clinical trials using standard Cochrane methodologies and assessed according to the GRADE approach.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-06-08 10:59:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no randomised clinical trials assessing antifibrinolytic amino acids for treating upper gastrointestinal bleeding in people with acute or chronic liver disease. We did not identify quasi-randomised, historically controlled, or observational studies in which we could assess harms.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-06-08 10:59:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This updated Cochrane review identified no randomised clinical trials assessing the benefits and harms of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease. The benefits and harms of antifibrinolytic amino acids need to be tested in randomised clinical trials. Unless randomised clinical trials are conducted to assess the trade-off between benefits and harms, we cannot recommend or refute antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver diseases.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-06-08 13:25:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2015-06-08 11:11:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CONDITION MODIFIED="2015-06-08 11:07:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Haemostasis is a physiological process that prevents and stops pathological bleeding. Haemostasis ensures blood vessel integrity by forming blood clots. After repairing the blood vessel integrity, the clot dissolves (<LINK REF="REF-Hedner-2002" TYPE="REFERENCE">Hedner 2002</LINK>). Abnormalities in haemostasis can result in bleeding (haemorrhage) or blood clots (thrombosis).</P>
<P>Acquired coagulopathies are complex disorders, usually involving a combination of multiple coagulation factor deficiencies, platelet dysfunction, and thrombocytopenia. People with liver disease are at high risk for presenting with acquired coagulopathy, and bleeding often complicates the clinical course of liver disease (<LINK REF="REF-van-der-Werf-2009" TYPE="REFERENCE">van der Werf 2009</LINK>; <LINK REF="REF-Pluta-2010" TYPE="REFERENCE">Pluta 2010</LINK>; <LINK REF="REF-Roberts-2010" TYPE="REFERENCE">Roberts 2010</LINK>; <LINK REF="REF-Kavanagh-2011" TYPE="REFERENCE">Kavanagh 2011</LINK>; <LINK REF="REF-Tripodi-2011" TYPE="REFERENCE">Tripodi 2011</LINK>; <LINK REF="REF-Violi-2011" TYPE="REFERENCE">Violi 2011</LINK>). Between 50% and 60% of people with cirrhosis may develop upper gastrointestinal bleeding induced by oesophageal variceal rupture. The situation is worsened by acquired coagulation disorders (<LINK REF="REF-van-Leerdam-2008" TYPE="REFERENCE">van Leerdam 2008</LINK>). Up to 24.8% of people with cirrhosis suffer from chronic consumption coagulopathy (<LINK REF="REF-Moreno-Abad_x00ed_a-1989" TYPE="REFERENCE">Moreno Abadía 1989</LINK>).</P>
<P>People with liver disease frequently have haemostatic abnormalities, which include accelerated fibrinolysis (<LINK REF="REF-T_x00e9_llez_x002d_Avila-2007" TYPE="REFERENCE">Téllez-Avila 2007</LINK>; <LINK REF="REF-Bennani_x002d_Baiti-2011" TYPE="REFERENCE">Bennani-Baiti 2011</LINK>; <LINK REF="REF-Kang-2011" TYPE="REFERENCE">Kang 2011</LINK>; <LINK REF="REF-Beier-2012" TYPE="REFERENCE">Beier 2012</LINK>). The pathogenesis of hyperfibrinolysis in alcoholic cirrhosis has been explained as a relative plasma plasminogen activator inhibitor type-1 deficiency and enhanced basal acute tissue plasminogen activator release (<LINK REF="REF-Ferguson-2008" TYPE="REFERENCE">Ferguson 2008</LINK>).</P>
<P>Hyperfibrinolysis is thought to contribute to bleeding that is associated with advanced cirrhosis and may be life-threatening (<LINK REF="REF-Violi-1993" TYPE="REFERENCE">Violi 1993</LINK>; <LINK REF="REF-Agarwal-2000" TYPE="REFERENCE">Agarwal 2000</LINK>; <LINK REF="REF-Hu-2001" TYPE="REFERENCE">Hu 2001</LINK>; <LINK REF="REF-Piscaglia-2001" TYPE="REFERENCE">Piscaglia 2001</LINK>; <LINK REF="REF-Colucci-2003" TYPE="REFERENCE">Colucci 2003</LINK>). The known risk of variceal bleeding suggests the existence of a circadian rhythm of fibrinolysis in cirrhosis (<LINK REF="REF-Piscaglia-2000" TYPE="REFERENCE">Piscaglia 2000</LINK>). Additionally, the risk of gastrointestinal bleeding in people with cirrhosis seems more strongly linked to their blood concentration of fibrin degradation products than to their Child-Pugh classification (<LINK REF="REF-Violi-1992" TYPE="REFERENCE">Violi 1992</LINK>). However, this finding has not been confirmed.</P>
</CONDITION>
<INTERVENTION MODIFIED="2015-06-08 11:07:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Drugs that reduce fibrinolysis are called antifibrinolytic drugs. In clinical practice only two drugs are used, tranexamic acid and aminocaproic acid. Both drugs are synthetic derivatives that exert their antifibrinolytic effect through the reversible blockade of lysine binding sites on the plasminogen molecules and thereby blocking the binding of plasminogen to fibrin and its activation and transformation to plasmin (<LINK REF="REF-McCormack-2012" TYPE="REFERENCE">McCormack 2012</LINK>). Tranexamic acid, the most widely studied antifibrinolytic drug, is seven to 10 times more potent than aminocaproic acid (<LINK REF="REF-Chiu-2002" TYPE="REFERENCE">Chiu 2002</LINK>). Both drugs have adverse effects involving the gastrointestinal tract (nausea, vomiting, abdominal pain, and diarrhoea), but the main risks are thrombotic complications (<LINK REF="REF-Mannucci-1998" TYPE="REFERENCE">Mannucci 1998</LINK>). Although tranexamic acid may be effective in people with upper gastrointestinal haemorrhage (<LINK REF="REF-Henry-1989" TYPE="REFERENCE">Henry 1989</LINK>), and in people with cirrhosis and hyperfibrinolysis (<LINK REF="REF-Gunawan-2006" TYPE="REFERENCE">Gunawan 2006</LINK>), there is a need to review the evidence systematically, taking into account the Cochrane methodology for conducting systematic reviews and meta-analyses, based on randomised clinical trials.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2015-06-08 11:11:20 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no systematic reviews or meta-analyses on antifibrinolytic amino acid administration to people with acute or chronic liver disease that is also complicated by upper gastrointestinal bleeding, apart from our own Cochrane Hepato-Biliary systematic reviews (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2006" TYPE="REFERENCE">Martí-Carvajal 2006</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK>; <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>). The present review represents an update of <LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-06-08 11:16:54 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>To assess the beneficial and harmful effects of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-06-08 13:25:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SELECTION_CRITERIA MODIFIED="2015-06-08 11:17:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_STUDIES MODIFIED="2015-06-08 11:11:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Randomised clinical trials irrespective of the design, publication status (unpublished or published as an article, abstract, or letter), language, and blinding. If cross-over trials were identified, we planned to use only data from the first intervention period. We intended to exclude quasi-randomised studies and prospective observational studies for the report on benefits and include them for data on harms.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-06-08 11:12:03 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>People with acute or chronic liver disease of any aetiology and experiencing upper gastrointestinal bleeding.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-06-08 11:17:01 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Antifibrinolytic amino acids administered at any dose, by any route of administration, and duration of treatment versus no intervention or placebo. Since upper gastrointestinal bleeding in people with liver disease requires different medical and endoscopic treatments (i.e., primary intervention), antifibrinolytic amino acids are considered as a supplementary intervention. Thus, for the purpose of the review, eligible randomised clinical trials had to compare the same primary interventions with and without antifibrinolytic amino acid drug supplementation.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-06-08 11:17:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-06-08 11:17:11 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Mortality.</LI>
<LI>Failure to control bleeding.</LI>
<LI>Serious adverse events. We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>), that is, any untoward medical occurrence that resulted in death, was life threatening, required hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability or incapacity, or was a congenital anomaly or birth defect. We considered all other adverse events as non-serious.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-06-08 11:17:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>Quality of life.</LI>
<LI>Non-serious adverse events.</LI>
<LI>Number of participants receiving a blood transfusion.</LI>
<LI>Number of blood transfusions.</LI>
<LI>Length of hospital stay.</LI>
<LI>Length of intensive care unit stay.</LI>
</UL>
<P>We planned to report the first seven of the above primary and secondary outcomes in the 'Summary of findings' table.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-06-08 12:44:39 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We searched The Cochrane Hepato-Biliary Controlled Trials Register (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (Ovid SP), EMBASE (Ovid SP), Science Citation Index EXPANDED, and LILACS to February 2015. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies with the time spans of the searches.</P>
<P>We looked through the reference lists of the retrieved publications and review articles. We also searched the following trial databases for ongoing and unpublished trials:</P>
<UL>
<LI>World Health Organization International Clinical Trials Registry Platform Search Portal (<A HREF="http://apps.who.int/trialsearch/">apps.who.int/trialsearch/</A>);</LI>
<LI>metaRegister of controlled trials (<A HREF="http://www.controlled-trials.com/mrct/search.html">www.controlled-trials.com/mrct/search.html</A>).</LI>
</UL>
<P>In future updates, we will also search the study reports at regulatory agencies (US Food and Drug Administration and European Medicines Agency) and trials at <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-06-08 13:25:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to summarise data using standard Cochrane methodologies (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>).</P>
<STUDY_SELECTION MODIFIED="2015-06-08 12:29:56 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We screened the search results for potentially relevant trials and independently assessed the trials for inclusion or exclusion using a pre-designed eligibility form, which was based on the inclusion criteria. We resolved disagreements through discussion until a consensus was reached. We found no randomised clinical trials for inclusion or any other study reporting data on harm.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-06-08 12:30:14 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>Due to the lack of randomised clinical trials, we could not follow the methodology as described in the review protocol (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2006" TYPE="REFERENCE">Martí-Carvajal 2006</LINK>). However, if we identify trials in the future, we will follow the described processes. We will use a form to extract data from each relevant trial (<LINK REF="REF-Zavala-2006" TYPE="REFERENCE">Zavala 2006</LINK>). We planned that two review authors would independently extract data from the trial publications and would contact the authors if data were missing. We planned that AMC would enter data into Review Manager 5 (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>), and IS would check the data. We also planned to extract information on study design and participant characteristics (age, sex, and disease severity as measured by the Child-Pugh score).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-06-08 12:30:53 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>If we identify randomised clinical trials fulfilling the inclusion criteria of our review, we will independently assess the risk of bias of each included trial according to the recommendations in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011a" TYPE="REFERENCE">Higgins 2011a</LINK>), The Cochrane Hepato-Biliary Module (<LINK REF="REF-Gluud-2015" TYPE="REFERENCE">Gluud 2015</LINK>), and methodological studies (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovi_x0107_-2012a" TYPE="REFERENCE">Savovi&#263; 2012a</LINK>; <LINK REF="REF-Savovi_x0107_-2012b" TYPE="REFERENCE">Savovi&#263; 2012b</LINK>). We will use the following definitions in the assessment of risk of bias.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI> Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent adjudicator.</LI>
<LI>Unclear risk of bias: the trial was described as randomised, but the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not, or may not have been, random. Quasi-randomised studies, those using dates, names, or admittance numbers in order to allocate participants, were inadequate and were excluded for the assessment of benefits but included for assessing harms.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: allocation was controlled by a central and independent randomisation unit, sequentially numbered, opaque and sealed envelopes or similar, so that intervention allocations could not have been foreseen in advance of, or during, enrolment.</LI>
<LI>Unclear risk of bias: the trial was described as randomised, but the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was known to the investigators who assigned participants, or if the study was quasi-randomised.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants and personnel</HEADING>
<UL>
<LI>Low risk of bias: it was mentioned that both participants and personnel providing the interventions were blinded, and the method of blinding was described, so that knowledge of allocation was prevented during the trial.</LI>
<LI>Unclear risk of bias: it was not mentioned if the trial was blinded, or the trial was described as blinded, but the method or extent of blinding was not described, so that knowledge of allocation was possible during the trial.</LI>
<LI>High risk of bias: the trial was not blinded, so that the allocation was known during the trial.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinded outcome assessment</HEADING>
<UL>
<LI>Low risk of bias: outcome assessment was carried out blinded for all relevant outcomes, and the method of blinding was described, so that knowledge of allocation was prevented.</LI>
<LI>Unclear risk of bias: blinding of outcome assessment was not described, or the outcome assessment was described as blinded, but the method of blinding was not described, so that knowledge of allocation was possible.</LI>
<LI>High risk of bias: outcome assessment was not blinded, so that the allocation was known to outcome assessors.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed to handle missing data.</LI>
<LI>Unclear risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: the trial reported the following pre-defined outcomes: mortality, failure to control bleeding, and serious adverse events. If the original trial protocol was available, the outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry (e.g., <A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), the outcomes sought should be those enumerated in the original protocol if the trial protocol was registered before or at the time that the trial was begun. If the trial protocol was registered after the trial was begun, those outcomes were not considered to be reliable.</LI>
<LI>Unclear risk of bias: not all pre-defined outcomes were reported fully, or it was unclear whether data on these outcomes were recorded or not.</LI>
<LI>High risk of bias: one or more pre-defined outcomes were not reported.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">For-profit bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of industry sponsorship or other type of for-profit support that may manipulate the trial design, conductance, or results of the trial.</LI>
<LI>Unclear risk of bias: the trial may or may not be free of for-profit bias as no information on clinical trial support or sponsorship was provided.</LI>
<LI>High risk of bias: the trial was sponsored by industry or received other type of for-profit support.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other bias domains that could put it at risk of bias.</LI>
<LI>Unclear risk of bias: the trial may or may not have been free of other domains that could put it at risk of bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias.</LI>
</UL>
<P>We will judge trials at low risk of bias if assessed with low risk of bias in all above domains. We will judge trials at high risk of bias if assessed with unclear risk of bias or high risk of bias in one or more of the above domains.</P>
<P>We will generate a 'Risk of bias' graph and a 'Risk of bias' summary to show a summary of this assessment.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-06-08 12:32:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>For binary outcomes, such as mortality, failure to control bleeding, and safety, we planned to calculate the risk ratio (RR) with 95% confidence interval (CI).</P>
<P>For continuous outcomes, such as number of participants receiving a blood transfusion, number of blood transfusions, length of hospital stay, and length of intensive care unit stay, we planned to calculate the mean difference (MD) with 95% CI.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-06-08 12:32:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the case of missing data on participants or missing statistics (such as standard deviations), we intended to contact the trial authors. If unsuccessful, we planned to base our main analysis on participants who had completed the trial, but we planned to perform sensitivity analysis for worse-case and best-case scenarios according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Section 16.1 (<LINK REF="REF-Higgins-2011b" TYPE="REFERENCE">Higgins 2011b</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-06-08 12:32:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We will quantify the impact of statistical heterogeneity using the I<SUP>2</SUP> statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If the identified trials are comparable enough, we planned to summarise their findings using a random-effects model. In the case of substantial heterogeneity (I<SUP>2</SUP> &gt; 50%), we planned to do further research to identify possible causes of heterogeneity, by exploring the impact of participants' characteristics.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-06-08 12:32:38 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to assess whether the review was subject to publication bias by using a funnel plot, which is usually used to illustrate variability between trials in a graphical way. We needed at least 10 trials in order to be able to make judgements about asymmetry and, if asymmetry was present, we planned to attempt to explore other causes for it (<LINK REF="REF-Sterne-2011" TYPE="REFERENCE">Sterne 2011</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-06-08 12:32:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We intended to carry out statistical analysis using Review Manager 5 software (<LINK REF="REF-RevMan-2014" TYPE="REFERENCE">RevMan 2014</LINK>). If the eligible trials were sufficiently comparable in their clinical characteristics, we planned to summarise their findings using the fixed-effect and the random-effects models according to the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>Section 9.4 (<LINK REF="REF-Deeks-2011" TYPE="REFERENCE">Deeks 2011</LINK>). In the case of statistically significant differences between the two models, we intended to report both. Otherwise, we planned to report the results of the model having the most conservative findings (<LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Trial sequential analysis</HEADING>
<P>A meta-analysis of cumulative data may run the risk of random errors ('play of chance') due to sparse data and repetitive analyses of the same data (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). In order to assess the risk of random errors in cumulative meta-analyses, we planned to conduct diversity-adjusted trial sequential analyses based on a required information size calculated from the proportion of participants with the outcome in the control group; an a priori set relative risk reduction of 20%, an alpha of 5%, beta of 20%, and the diversity in the meta-analysis (<LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>; <LINK REF="REF-TSA-2011" TYPE="REFERENCE">TSA 2011</LINK>). We planned to conduct sensitivity analysis of the trial sequential analyses to estimate the need for further trials.</P>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-06-08 13:25:09 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We anticipated clinical heterogeneity in the effects of the intervention and we propose to conduct the following subgroup analyses when data become available.</P>
<UL>
<LI>Trials with low risk of bias (or with lower risk of bias) compared to trials with high risk of bias.</LI>
<LI>Participants with cirrhosis compared to participants without cirrhosis.</LI>
<LI>Child-Pugh classification A compared to classification B and compared to classification C.</LI>
<LI>Participants with acute liver disease compared to participants with chronic liver disease.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-06-08 12:32:58 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to seek data on the number of participants randomised to the intervention and control groups, irrespective of compliance and whether or not the participants were later thought to be ineligible or otherwise excluded from the treatment group or follow-up. If we were unable to do so, we planned to record whether the results of each trial were based on an intention-to-treat analysis or on available participant analysis.</P>
<P>We planned to conduct sensitivity analyses including only randomised trials with low risk of bias and to perform best-case and worst-case scenario analyses if there are missing participants.</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings tables</HEADING>
<P>We intended to use the principles of the GRADE system (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>) in order to assess the quality of the body of evidence associated with specific outcomes (mortality, failure to control bleeding, number of participants receiving a blood transfusion, number of blood transfusions, and adverse events) in our review and construct a 'Summary of findings' table using the GRADEPro software (<A HREF="http://ims.cochrane.org/revman/other-resources/gradepro">ims.cochrane.org/revman/other-resources/gradepro</A>). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence considers within-study risk of bias, the indirectness of the evidence, heterogeneity of the data, imprecision of effect estimates, and risk of publication bias (<LINK REF="REF-Balshem-2011" TYPE="REFERENCE">Balshem 2011</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2011c" TYPE="REFERENCE">Guyatt 2011c</LINK>; <LINK REF="REF-Guyatt-2011d" TYPE="REFERENCE">Guyatt 2011d</LINK>; <LINK REF="REF-Guyatt-2011e" TYPE="REFERENCE">Guyatt 2011e</LINK>; <LINK REF="REF-Guyatt-2011f" TYPE="REFERENCE">Guyatt 2011f</LINK>; <LINK REF="REF-Guyatt-2011g" TYPE="REFERENCE">Guyatt 2011g</LINK>; <LINK REF="REF-Guyatt-2011h" TYPE="REFERENCE">Guyatt 2011h</LINK>; <LINK REF="REF-Guyatt-2011i" TYPE="REFERENCE">Guyatt 2011i</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>; <LINK REF="REF-Guyatt-2013b" TYPE="REFERENCE">Guyatt 2013b</LINK>). We planned to assess the imprecision according to <LINK REF="REF-Jakobsen-2014" TYPE="REFERENCE">Jakobsen 2014</LINK>.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-06-08 12:33:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2015-06-08 12:33:26 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified 130 references after removing duplicates through the initial bibliographical searches. After manually checking the titles and abstracts, we excluded 129 records. We obtained the full text of one article, but excluded it as it contained clinical guidelines (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table; <LINK REF="STD-Colle-2011" TYPE="STUDY">Colle 2011</LINK>). Therefore, no studies remained to be evaluated further as none of the studies attempted to answer the research question of this systematic review. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-06-08 12:33:23 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We included no trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-06-08 12:33:35 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We identified no randomised clinical trials that were eligible for inclusion in this Cochrane review. We identified no ongoing trials. Thus, with the lack of trials, we were unable to assess benefits and harms of antifibrinolytic amino acids given as supplementary treatment to people with upper gastrointestinal bleeding due to acute or chronic liver disease and having acquired coagulation disorders.</P>
<P>We identified no quasi-randomised, historically controlled, or observational studies so we could not assess the occurrence of harms in such studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-06-08 12:34:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2015-06-08 12:34:17 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no evidence from randomised clinical trials supporting or refuting the use of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
<P>The searches identified no data reporting on harms from quasi-randomised studies and prospective observational studies.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-06-08 12:34:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The updated search found no randomised clinical trials for us to be able to support or refute the use of antifibrinolytic amino acids in people with upper gastrointestinal bleeding due to acute or chronic liver disease and associated with acquired coagulation disorders. This fact is surprising considering the number of people worldwide who experience this severe complication due to the liver disease. The liver plays a key role in the molecular mechanisms that finely co-ordinate fibrin formation and fibrinolysis (<LINK REF="REF-Cesarman_x002d_Maus-2005" TYPE="REFERENCE">Cesarman-Maus 2005</LINK>). Increased fibrinolysis is a common finding in people with advanced liver disease (<LINK REF="REF-Amitrano-2002" TYPE="REFERENCE">Amitrano 2002</LINK>; <LINK REF="REF-Van-Thiel-2004" TYPE="REFERENCE">Van Thiel 2004</LINK>). The enhanced fibrinolysis is a product of increased plasma levels of tissue plasminogen activator, thrombin-antithrombin complexes, plasma antiplasmin complexes, and plasma D-dimer (<LINK REF="REF-Van-Thiel-2004" TYPE="REFERENCE">Van Thiel 2004</LINK>; <LINK REF="REF-Ferguson-2008" TYPE="REFERENCE">Ferguson 2008</LINK>).</P>
<P>At least three explanations could potentially support the lack of randomised clinical trials assessing antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders. First, the clinical relevance of hyperfibrinolysis with the bleeding tendency of people with cirrhosis has not been clearly established (<LINK REF="REF-Amitrano-2002" TYPE="REFERENCE">Amitrano 2002</LINK>); however, <LINK REF="REF-Gunawan-2006" TYPE="REFERENCE">Gunawan 2006</LINK> has shown the efficacy and safety of &#949;-aminocaproic acid in this population. These data were gathered from a non-randomised controlled trial. Second, chronic liver disease is characterised by hyperfibrinolysis (<LINK REF="REF-Agarwal-2000" TYPE="REFERENCE">Agarwal 2000</LINK>; <LINK REF="REF-Hu-2001" TYPE="REFERENCE">Hu 2001</LINK>; <LINK REF="REF-Van-Thiel-2004" TYPE="REFERENCE">Van Thiel 2004</LINK>), and, in acute liver failure, a state of reduced fibrinolysis occurs (<LINK REF="REF-Van-Thiel-2004" TYPE="REFERENCE">Van Thiel 2004</LINK>). Third, the administration of antifibrinolytic agents in people with liver cirrhosis is limited by the risk of thrombosis when disseminated intravascular coagulation is present (<LINK REF="REF-Amitrano-2002" TYPE="REFERENCE">Amitrano 2002</LINK>).</P>
<P>It is widely known that clinicians make practical decisions, often on the basis of inadequate information. Decisions about treatment should be made based on the results of randomised clinical trials (<LINK REF="REF-Alderson-2004" TYPE="REFERENCE">Alderson 2004</LINK>; <LINK REF="REF-Chalmers-2004" TYPE="REFERENCE">Chalmers 2004</LINK>). It is possible that some trials have been carried out but the results were negative, and thus they remain unpublished.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-06-08 12:34:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We were unable to identify evidence from randomised clinical trials to support or refute the use of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-06-08 12:34:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In the process of performing this systematic review, we also planned to look for 'significance-chasing biases', which include, among others, publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. However, this Cochrane review contained no trials and, as such, we did not evaluate risk of bias. Trials with 'negative' results may have remained unpublished as suppression of information on specific outcomes may have occurred (<LINK REF="REF-Ioannidis-2010" TYPE="REFERENCE">Ioannidis 2010</LINK>). We have been unable to identify evidence from randomised clinical trials supporting the use of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-06-08 12:34:31 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no other studies or reviews. Our review could not provide evidence from randomised clinical trials in order to support or refute the use of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver disease associated with acquired coagulation disorders.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-06-08 12:35:04 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<IMPLICATIONS_PRACTICE MODIFIED="2015-06-08 12:35:04 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>We found no randomised clinical trials of antifibrinolytic amino acids for upper gastrointestinal bleeding in people with liver disease for inclusion in this updated Cochrane review. Therefore, it was not possible to determine the benefits and harms of the antifibrinolytic amino acids in this clinical entity. Accordingly, we cannot recommend or refute the use of antifibrinolytic amino acids in people with upper gastrointestinal bleeding associated with acute or chronic liver disease.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-06-08 12:35:04 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>This updated Cochrane review has identified the need for well-designed, adequately powered randomised clinical trials to assess the benefits and harms of antifibrinolytic amino acids in people with upper gastrointestinal bleeding due to acute or chronic liver disease. According to <LINK REF="REF-Brown-2006" TYPE="REFERENCE">Brown 2006</LINK>, questions such as the following could be answered using randomised clinical trials. What regimen is most effective: single or combined? When can intravenous antifibrinolytic regimens be switched to oral administration? The randomised clinical trials should include participant-relevant clinical outcomes such as mortality, failure to control bleeding, and adverse events.</P>
<P>Potential trials should be planned according to SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement (<LINK REF="REF-Chan-2013a" TYPE="REFERENCE">Chan 2013a</LINK>; <LINK REF="REF-Chan-2013b" TYPE="REFERENCE">Chan 2013b</LINK>). The trials should be reported according to the CONSORT (CONsolidated Standards Of Reporting Trials) statement (<LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>), which helps in improving the quality of reporting of benefits and harms in clinical research (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>; <LINK REF="REF-Moher-2010" TYPE="REFERENCE">Moher 2010</LINK>). Trials should include participant-centred outcomes such as mortality, re-bleeding, and serious and non-serious adverse events as recommended by the Patient-Centered Outcomes Research Institute (P-CORI) statement (<LINK REF="REF-Selby-2013" TYPE="REFERENCE">Selby 2013</LINK>; <LINK REF="REF-Frank-2014" TYPE="REFERENCE">Frank 2014</LINK>; <LINK REF="REF-Selby-2014" TYPE="REFERENCE">Selby 2014</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-06-08 12:46:13 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The review authors express their gratitude to Pedro I Martí-Carvajal<SUP>&#10015;</SUP>, Venezuela, who worked on the first updated version of this review (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2012" TYPE="REFERENCE">Martí-Carvajal 2012</LINK>), Sarah Louise Klingenberg of the Cochrane Hepato-Biliary for conducting the search of references, and the Iberoamerican Cochrane Centre.</P>
<P>Contact Editors: Brian Davidson, UK; Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-06-08 12:49:44 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>In 2004 and 2007, Arturo Martí-Carvajal was employed by Eli Lilly to run a four-hour workshop on 'How to critically appraise clinical trials on osteoporosis and how to teach this'. This activity was not related to his work with The Cochrane Collaboration or any Cochrane review.</P>
<P>Ivan Solà: none known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-06-08 12:49:36 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>AMC was the lead author of the protocol and the review, and acted as guarantor of the review.<BR/>IS drafted the review.</P>
<P>Both authors approved the final review manuscript for publication.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-06-08 12:36:24 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<UL>
<LI>We re-arranged the outcomes in terms of what the most relevant outcomes are for the people with liver disease.</LI>
<LI>We updated the risk of bias domains following latest recommendations.</LI>
<LI>We planned trial sequential analysis and will apply it when we identify trials for inclusion.</LI>
<LI>We planned 'Summary of findings' tables and the outcomes reported within them and will apply these when we identify trials for inclusion.</LI>
</UL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2015-06-08 13:31:19 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<P>The team of authors changed. We thank Graciela Nicita for her previous contribution to the review version, published in 2007 (<LINK REF="REF-Mart_x00ed__x002d_Carvajal-2007" TYPE="REFERENCE">Martí-Carvajal 2007</LINK>). Pedro Martí-Carvajal passed away in 2012.</P>
<P>This review will not be updated until relevant for the review randomised clinical trials are published.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-06-08 12:42:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2015-03-17 17:51:26 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal"/>
<EXCLUDED_STUDIES MODIFIED="2015-03-17 17:51:26 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Colle-2011" MODIFIED="2015-03-17 17:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="Colle 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-03-17 17:51:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Colle I, Wilmer A, Le Moine O, Debruyne R, Delwaide J, Dhondt E, et al</AU>
<TI>Upper gastrointestinal tract bleeding management: Belgian guidelines for adults and children</TI>
<SO>Acta Gastro-Enterologica Belgica</SO>
<YR>2011</YR>
<VL>74</VL>
<NO>1</NO>
<PG>45-66</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:51:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-03-17 16:33:31 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-06-08 12:42:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2015-06-08 12:42:48 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Agarwal-2000" MODIFIED="2015-03-17 17:44:21 +0100" MODIFIED_BY="[Empty name]" NAME="Agarwal 2000" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal S, Joyner KA Jr, Swaim MW</AU>
<TI>Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>11</NO>
<PG>3218-24</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:44:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2004" MODIFIED="2015-03-17 17:44:16 +0100" MODIFIED_BY="[Empty name]" NAME="Alderson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>476-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:44:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Amitrano-2002" MODIFIED="2015-03-17 17:44:08 +0100" MODIFIED_BY="[Empty name]" NAME="Amitrano 2002" TYPE="JOURNAL_ARTICLE">
<AU>Amitrano L, Guardascione MA, Brancaccio V, Balzano A</AU>
<TI>Coagulation disorders in liver disease</TI>
<SO>Seminars in Liver Disease</SO>
<YR>2002</YR>
<VL>22</VL>
<PG>83-96</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:44:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Balshem-2011" MODIFIED="2015-03-17 17:43:59 +0100" MODIFIED_BY="[Empty name]" NAME="Balshem 2011" TYPE="JOURNAL_ARTICLE">
<AU>Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 3. Rating the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>401-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Beier-2012" MODIFIED="2015-03-17 17:43:53 +0100" MODIFIED_BY="[Empty name]" NAME="Beier 2012" TYPE="JOURNAL_ARTICLE">
<AU>Beier JI, Arteel GE</AU>
<TI>Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism</TI>
<SO>Experimental Biology and Medicine</SO>
<YR>2012</YR>
<VL>237</VL>
<NO>1</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bennani_x002d_Baiti-2011" MODIFIED="2015-03-17 17:43:47 +0100" MODIFIED_BY="[Empty name]" NAME="Bennani-Baiti 2011" TYPE="JOURNAL_ARTICLE">
<AU>Bennani-Baiti N, Daw HA</AU>
<TI>Primary hyperfibrinolysis in liver disease: a critical review</TI>
<SO>Clinical Advances in Hematology &amp; Oncology</SO>
<YR>2011</YR>
<VL>9</VL>
<NO>3</NO>
<PG>250-2</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2015-03-17 17:43:38 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:38 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2015-06-08 12:37:04 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2012-07-13 14:12:42 +0200" MODIFIED_BY="Arturo J Marti-Carvajal">
<IDENTIFIER TYPE="PUBMED" VALUE="18824466"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brown-2006" MODIFIED="2015-03-17 17:43:31 +0100" MODIFIED_BY="[Empty name]" NAME="Brown 2006" TYPE="JOURNAL_ARTICLE">
<AU>Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al</AU>
<TI>How to formulate research recommendations</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7572</NO>
<PG>804-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Cesarman_x002d_Maus-2005" MODIFIED="2015-03-17 17:43:25 +0100" MODIFIED_BY="[Empty name]" NAME="Cesarman-Maus 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cesarman-Maus G, Hajjar KA</AU>
<TI>Molecular mechanisms of fibrinolysis</TI>
<SO>British Journal of Haematology</SO>
<YR>2005</YR>
<VL>129</VL>
<PG>307-21</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2004" MODIFIED="2015-03-17 17:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Chalmers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Well informed uncertainties about the effects of treatments</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>475-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:43:17 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013a" MODIFIED="2015-03-17 16:53:43 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al</AU>
<TI>SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>e7586</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:53:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013b" MODIFIED="2015-03-17 16:53:16 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al</AU>
<TI>SPIRIT 2013 statement: defining standard protocol items for clinical trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2013</YR>
<VL>158</VL>
<NO>3</NO>
<PG>200-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:52:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chiu-2002" MODIFIED="2015-03-17 16:53:52 +0100" MODIFIED_BY="[Empty name]" NAME="Chiu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chiu J, Ketchum LH, Reid TJ</AU>
<TI>Transfusion-sparing hemostatic agents</TI>
<SO>Current Opinion in Hematology</SO>
<YR>2002</YR>
<VL>9</VL>
<PG>544-50</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:53:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Colucci-2003" MODIFIED="2015-03-17 16:53:58 +0100" MODIFIED_BY="[Empty name]" NAME="Colucci 2003" TYPE="JOURNAL_ARTICLE">
<AU>Colucci M, Binetti BM, Branca MG, Clerici C, Morelli A, Semeraro N, et al</AU>
<TI>Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>230-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:53:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2011" MODIFIED="2015-06-08 12:37:16 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Deeks 2011" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2008" MODIFIED="2015-03-17 16:54:07 +0100" MODIFIED_BY="[Empty name]" NAME="Ferguson 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC</AU>
<TI>Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency</TI>
<SO>Thrombosis Research</SO>
<YR>2008</YR>
<VL>121</VL>
<PG>675-80</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:54:07 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Frank-2014" MODIFIED="2015-03-17 17:46:59 +0100" MODIFIED_BY="[Empty name]" NAME="Frank 2014" TYPE="JOURNAL_ARTICLE">
<AU>Frank L, Basch E, Selby JV</AU>
<TI>The PCORI perspective on patient-centered outcomes research</TI>
<SO>JAMA</SO>
<YR>2014</YR>
<VL>312</VL>
<NO>15</NO>
<PG>1513-4</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:46:59 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2015" MODIFIED="2015-06-08 12:36:44 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Gluud 2015" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL</AU>
<TI>Cochrane Hepato-Biliary Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2015, Issue 3. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gunawan-2006" MODIFIED="2015-05-18 16:28:31 +0200" MODIFIED_BY="[Empty name]" NAME="Gunawan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gunawan B, Runyon B</AU>
<TI>The efficacy and safety of epsilon-aminocaproic acid treatment in patients with cirrhosis and hyperfibrinolysis</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2006</YR>
<VL>23</VL>
<PG>115-20</PG>
<IDENTIFIERS MODIFIED="2015-05-18 16:28:31 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2015-06-07 22:28:55 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>380-2</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:34:52 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2015-06-07 22:28:51 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al</AU>
<TI>GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>383-94</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:55:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011c" MODIFIED="2015-06-07 22:28:47 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011c" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, et al</AU>
<TI>GRADE guidelines: 2. Framing the question and deciding on important outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>395-400</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:55:29 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011d" MODIFIED="2015-06-07 22:28:40 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011d" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 4. Rating the quality of evidence - study limitations (risk of bias)</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>407-15</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:55:14 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011e" MODIFIED="2015-06-07 22:28:35 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011e" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al</AU>
<TI>GRADE guidelines: 5. Rating the quality of evidence - publication bias</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1277-82</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:54:40 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011f" MODIFIED="2015-06-07 22:28:29 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011f" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al</AU>
<TI>GRADE guidelines 6. Rating the quality of evidence - imprecision</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1283-93</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:54:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011g" MODIFIED="2015-06-07 22:28:21 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011g" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 7. Rating the quality of evidence - inconsistency</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1294-302</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:54:31 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011h" MODIFIED="2015-06-07 22:28:15 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011h" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al</AU>
<TI>GRADE guidelines: 8. Rating the quality of evidence - indirectness</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1303-10</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:54:47 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011i" MODIFIED="2015-06-07 22:28:10 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2011i" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:55:02 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2015-06-08 12:37:32 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Guyatt 2013a" TYPE="OTHER">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines 12. Preparing summary of findings tables-binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS MODIFIED="2015-03-17 16:57:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013b" MODIFIED="2015-06-07 22:29:05 +0200" MODIFIED_BY="Anne Lawson" NAME="Guyatt 2013b" TYPE="OTHER">
<AU>Guyatt G, Oxman AD, Sultan S, Brozek J, Glasziou P, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines 11 - making an overall rating of confidence in effect estimates for a single outcome and for all outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>151-7</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:36:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hedner-2002" MODIFIED="2015-06-07 22:10:00 +0200" MODIFIED_BY="Anne Lawson" NAME="Hedner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hedner U</AU>
<TI>General haemostatic agents - fact or fiction?</TI>
<SO>Pathophysiology of Haemostasis and Thrombosis</SO>
<YR>2002</YR>
<VL>32 Suppl 1</VL>
<PG>33-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:53 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Henry-1989" MODIFIED="2015-03-17 17:42:45 +0100" MODIFIED_BY="[Empty name]" NAME="Henry 1989" TYPE="JOURNAL_ARTICLE">
<AU>Henry DA, O'Connell DL</AU>
<TI>Effects of fibrinolytic inhibitors on mortality from upper gastrointestinal haemorrhage</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1989</YR>
<VL>298</VL>
<NO>6681</NO>
<PG>1142-8</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:45 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-03-17 17:42:37 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011a" MODIFIED="2015-06-08 12:37:45 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Higgins 2011a" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011b" MODIFIED="2015-06-07 22:29:54 +0200" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG</AU>
<TI>Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2001" MODIFIED="2015-03-17 17:38:11 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hu KQ, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB</AU>
<TI>Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>1581-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:38:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2015-03-26 13:24:54 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>Pennsylvania</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" MODIFIED="2015-03-17 17:42:20 +0100" MODIFIED_BY="[Empty name]" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<PG>781-8</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2010" MODIFIED="2012-07-04 12:51:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NAME="Ioannidis 2010" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP</AU>
<TI>The art of getting it wrong</TI>
<SO>Research Synthesis Methods</SO>
<YR>2010</YR>
<VL>1</VL>
<NO>3-4</NO>
<PG>169-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jakobsen-2014" MODIFIED="2015-05-18 16:28:53 +0200" MODIFIED_BY="[Empty name]" NAME="Jakobsen 2014" TYPE="JOURNAL_ARTICLE">
<AU>Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J</AU>
<TI>The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2014</YR>
<VL>14</VL>
<PG>34</PG>
<IDENTIFIERS MODIFIED="2015-05-18 16:28:53 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kang-2011" MODIFIED="2015-03-17 17:42:04 +0100" MODIFIED_BY="[Empty name]" NAME="Kang 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kang LI, Mars WM</AU>
<TI>Fibrinolytic factors in liver fibrosis</TI>
<SO>Current Pharmaceutical Biotechnology</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>9</NO>
<PG>1441-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:04 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kavanagh-2011" MODIFIED="2015-03-17 17:42:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kavanagh 2011" TYPE="JOURNAL_ARTICLE">
<AU>Kavanagh C, Shaw S, Webster CR</AU>
<TI>Coagulation in hepatobiliary disease</TI>
<SO>Journal of Veterinary Emergency and Critical Care</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>6</NO>
<PG>589-604</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:42:10 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2012-07-04 10:50:21 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2015-06-08 12:38:07 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-06-07 22:48:38 +0200" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2015-06-07 22:48:38 +0200" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mannucci-1998" MODIFIED="2015-03-26 13:26:27 +0100" MODIFIED_BY="[Empty name]" NAME="Mannucci 1998" TYPE="JOURNAL_ARTICLE">
<AU>Mannucci PM</AU>
<TI>Hemostatic drugs</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>339</VL>
<NO>4</NO>
<PG>245-53</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:38:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-McCormack-2012" MODIFIED="2015-03-17 17:41:49 +0100" MODIFIED_BY="[Empty name]" NAME="McCormack 2012" TYPE="JOURNAL_ARTICLE">
<AU>McCormack PL</AU>
<TI>Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis</TI>
<SO>Drugs</SO>
<YR>2012</YR>
<VL>72</VL>
<NO>5</NO>
<PG>585-617</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:41:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2012-07-04 10:50:21 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2010" MODIFIED="2015-03-17 17:38:30 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 2010" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2010</YR>
<VL>340</VL>
<PG>c869</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:38:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moreno-Abad_x00ed_a-1989" MODIFIED="2015-03-17 17:38:43 +0100" MODIFIED_BY="[Empty name]" NAME="Moreno Abadía 1989" TYPE="JOURNAL_ARTICLE">
<AU>Moreno Abadía V, Bermúdez García JM, Maldonado Martín A, Rico Irles J</AU>
<TI>The incidence of consumption coagulopathy in liver cirrhosis</TI>
<SO>Anales de Medicina Interna</SO>
<YR>1989</YR>
<VL>6</VL>
<PG>466-71</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:38:43 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Piscaglia-2000" MODIFIED="2015-03-17 17:41:39 +0100" MODIFIED_BY="[Empty name]" NAME="Piscaglia 2000" TYPE="JOURNAL_ARTICLE">
<AU>Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, et al</AU>
<TI>Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>349-57</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:41:39 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Piscaglia-2001" MODIFIED="2015-03-17 17:41:32 +0100" MODIFIED_BY="[Empty name]" NAME="Piscaglia 2001" TYPE="JOURNAL_ARTICLE">
<AU>Piscaglia F, Donati G, Giannini R, Bolondi L</AU>
<TI>Liver cirrhosis, ascites, and hyperfibrinolysis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>3222</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:41:32 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Pluta-2010" MODIFIED="2015-03-17 17:41:25 +0100" MODIFIED_BY="[Empty name]" NAME="Pluta 2010" TYPE="JOURNAL_ARTICLE">
<AU>Pluta A, Gutkowski K, Hartleb M</AU>
<TI>Coagulopathy in liver diseases</TI>
<SO>Advances in Medical Sciences</SO>
<YR>2010</YR>
<VL>55</VL>
<NO>1</NO>
<PG>16-21</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:41:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2014" MODIFIED="2015-06-08 12:38:17 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="RevMan 2014" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2014</YR>
<EN>5.3</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2010" MODIFIED="2015-03-17 17:38:58 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 2010" TYPE="JOURNAL_ARTICLE">
<AU>Roberts LN, Patel RK, Arya R</AU>
<TI>Haemostasis and thrombosis in liver disease</TI>
<SO>British Journal of Haematology</SO>
<YR>2010</YR>
<VL>148</VL>
<NO>4</NO>
<PG>507-21</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:38:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012a" MODIFIED="2015-06-08 12:38:30 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Savovi&#263; 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovi_x0107_-2012b" MODIFIED="2015-06-08 12:38:39 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Savovi&#263; 2012b" TYPE="JOURNAL_ARTICLE">
<AU>Savovi&#263; J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2012-07-04 10:50:21 +0200" MODIFIED_BY="Sarah L Klingenberg" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Selby-2013" MODIFIED="2015-05-18 16:29:13 +0200" MODIFIED_BY="[Empty name]" NAME="Selby 2013" TYPE="JOURNAL_ARTICLE">
<AU>Selby JV</AU>
<TI>The patient-centered outcomes research institute: a 2013 agenda for "research done differently"</TI>
<SO>Population Health Management</SO>
<YR>2013</YR>
<VL>16</VL>
<NO>2</NO>
<PG>69-70</PG>
<IDENTIFIERS MODIFIED="2015-05-18 16:29:13 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Selby-2014" MODIFIED="2015-05-18 16:29:22 +0200" MODIFIED_BY="[Empty name]" NAME="Selby 2014" TYPE="OTHER">
<AU>Selby JV</AU>
<TI>Patient-Centered Outcomes Research Institute seeks to find out what works best by involving 'end-users' from the beginning</TI>
<SO>Journal of Comparative Effectiveness Research</SO>
<YR>2014</YR>
<VL>3</VL>
<NO>2</NO>
<PG>125-9</PG>
<IDENTIFIERS MODIFIED="2015-05-18 16:29:22 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sterne-2011" MODIFIED="2015-03-17 17:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="Sterne 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al</AU>
<TI>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2011</YR>
<VL>343</VL>
<PG>d4002</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:39:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2015-03-17 17:39:22 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:39:22 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2015-03-17 17:39:30 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:39:30 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2015-06-08 12:42:18 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for trial sequential analysis (TSA), 2011</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>(accessed 26 March 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tripodi-2011" MODIFIED="2015-03-26 13:28:56 +0100" MODIFIED_BY="[Empty name]" NAME="Tripodi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Tripodi A, Mannucci PM</AU>
<TI>The coagulopathy of chronic liver disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>2011</YR>
<VL>365</VL>
<NO>2</NO>
<PG>147-56</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:39:37 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-TSA-2011" MODIFIED="2015-06-08 12:42:37 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="TSA 2011" TYPE="COMPUTER_PROGRAM">
<TI>TSA - trial sequential analysis</TI>
<YR>2011</YR>
<EN>0.9 Beta</EN>
<PB>Copenhagen Trial Unit</PB>
<CY>Copenhagen</CY>
<MD>www.ctu.dk/tsa/downloads.aspx</MD>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-T_x00e9_llez_x002d_Avila-2007" MODIFIED="2015-06-07 22:42:05 +0200" MODIFIED_BY="Anne Lawson" NAME="Téllez-Avila 2007" TYPE="JOURNAL_ARTICLE">
<AU>Téllez-Avila FI, Chávez-Tapia NC, Torre-Delgadillo A</AU>
<TI>Coagulation disorders in cirrhosis</TI>
<SO>Revista de Investigación Clínica</SO>
<YR>2007</YR>
<VL>59</VL>
<PG>153-60</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:39:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Werf-2009" MODIFIED="2015-03-17 17:40:05 +0100" MODIFIED_BY="[Empty name]" NAME="van der Werf 2009" TYPE="JOURNAL_ARTICLE">
<AU>van der Werf J, Porte RJ, Lisman T</AU>
<TI>Hemostasis in patients with liver disease</TI>
<SO>Acta Gastro-Enterologica Belgica</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>4</NO>
<PG>433-40</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:05 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-van-Leerdam-2008" MODIFIED="2015-03-17 17:40:13 +0100" MODIFIED_BY="[Empty name]" NAME="van Leerdam 2008" TYPE="JOURNAL_ARTICLE">
<AU>van Leerdam ME</AU>
<TI>Epidemiology of acute upper gastrointestinal bleeding</TI>
<SO>Best Practice &amp; Research. Clinical Gastroenterology</SO>
<YR>2008</YR>
<VL>22</VL>
<PG>209-24</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:13 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Van-Thiel-2004" MODIFIED="2015-06-08 12:42:25 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Van Thiel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Van Thiel DH, George M, Mindikoglu AL, Baluch MH, Dhillon S</AU>
<TI>Coagulation and fibrinolysis in individuals with advanced liver disease</TI>
<TO>Geç dönem karaciðer hastalýklarýnda koagulasyon ve fibrinolizis</TO>
<SO>Turkish Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>67-72</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:20 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Violi-1992" MODIFIED="2015-03-17 17:40:25 +0100" MODIFIED_BY="[Empty name]" NAME="Violi 1992" TYPE="JOURNAL_ARTICLE">
<AU>Violi F, Ferro D, Basili S, Quintarelli C, Saliola M, Alessandri C, et al</AU>
<TI>Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis</TI>
<SO>Hepatology</SO>
<YR>1992</YR>
<VL>15</VL>
<PG>672-6</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:25 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Violi-1993" MODIFIED="2015-03-17 17:40:33 +0100" MODIFIED_BY="[Empty name]" NAME="Violi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Violi F, Ferro D, Basili S, Quintarelli C, Musca A, Cordova C, et al</AU>
<TI>Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation abnormalities in liver cirrhosis</TI>
<SO>Hepatology</SO>
<YR>1993</YR>
<VL>17</VL>
<PG>78-83</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:33 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Violi-2011" MODIFIED="2015-03-17 17:40:42 +0100" MODIFIED_BY="[Empty name]" NAME="Violi 2011" TYPE="JOURNAL_ARTICLE">
<AU>Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, Burroughs AK</AU>
<TI>Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction?</TI>
<SO>Journal of Hepatology</SO>
<YR>2011</YR>
<VL>55</VL>
<NO>6</NO>
<PG>1415-27</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:42 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2015-03-17 17:40:49 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:49 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2015-03-17 17:40:58 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:40:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2015-03-17 17:41:06 +0100" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS MODIFIED="2015-03-17 17:41:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Zavala-2006" MODIFIED="2015-06-08 12:42:48 +0200" MODIFIED_BY="Dimitrinka Nikolova" NAME="Zavala 2006" TYPE="COMPUTER_PROGRAM">
<TI>Zavala D, Martí A, Peña-Martí G, Comunián G. Sheet to enter data for performing a Cochrane review</TI>
<YR>2006</YR>
<PB>Universidad de Carabobo</PB>
<CY>Valencia, Venezuela</CY>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-03-26 13:11:17 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2006" MODIFIED="2015-03-26 13:11:17 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Marti-Carvajal AJ, Pérez-Requejo JL</AU>
<TI>Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-03-26 13:11:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-26 13:11:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006007"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2007" MODIFIED="2015-03-26 13:07:55 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2007" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I, Nicita G</AU>
<TI>Antifibrinolytic amino acids for acquired coagulation disorders in patients with liver disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2015-03-17 18:06:30 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-16 11:44:12 +0100" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.CD006007.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mart_x00ed__x002d_Carvajal-2012" MODIFIED="2015-03-26 13:09:31 +0100" MODIFIED_BY="[Empty name]" NAME="Martí-Carvajal 2012" TYPE="COCHRANE_REVIEW">
<AU>Martí-Carvajal AJ, Solà I, Martí-Carvajal PI</AU>
<TI>Antifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>9</NO>
<IDENTIFIERS MODIFIED="2015-03-17 15:55:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-17 15:55:59 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006007.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2015-02-28 21:07:24 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-03-17 16:33:31 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-06-18 13:43:40 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-06-18 13:43:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colle-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-18 13:43:40 +0200" MODIFIED_BY="Arturo J Marti-Carvajal">
<P>Clinical guidelines.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-03-17 16:33:31 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-06-18 14:32:46 +0200" MODIFIED_BY="Arturo J Marti-Carvajal" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-09-23 15:27:32 +0200" MODIFIED_BY="dimitrinka nikolova"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES MODIFIED="2015-06-07 23:04:35 +0200" MODIFIED_BY="Anne Lawson">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-06-07 23:04:35 +0200" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram for this update (26 February 2015).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAKWCAYAAABj+x9xAAA8HElEQVR42u3df8QWafv48YckSbIk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==
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-06-08 14:01:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<APPENDIX ID="APP-01" MODIFIED="2015-06-08 14:01:50 +0200" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<TITLE MODIFIED="2012-08-01 12:32:31 +0200" MODIFIED_BY="dimitrinka nikolova">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-06-08 14:01:50 +0200" MODIFIED_BY="Dimitrinka Nikolova">
<TABLE COLS="3" ROWS="9">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Name of database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Timespan of search</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>'antifibrinolytic amino acid*' OR 'aminocaproic acid*' OR 'tranexamic acid*'</P>
<P/>
<P>13 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials in <I>The Cochrane Library</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 2 of 12, 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Antifibrinolytic Agentsexplode all trees</P>
<P>#2 MeSH descriptor Aminocaproic Acids explode all trees in MeSH products</P>
<P>#3 MeSH descriptor Tranexamic Acidexplode all trees in MeSH products</P>
<P>#4 antifibrinolytic amino acid* or aminocaproic acid* or tranexamic acid* in All Fields in all products</P>
<P>#5 (#1 OR #2 OR #3 OR #4)</P>
<P>#6 MeSH descriptor Blood Coagulation Disorders explode all trees in MeSH products</P>
<P>#7 acquired coagulation disorder* in All Fieldsin all products</P>
<P>#8 (#6 OR #7)</P>
<P>#9 MeSH descriptor Liver Diseasesexplode all trees in MeSH products</P>
<P>#10 liver disease* in All Fieldsin all products</P>
<P>#11 (#9 OR #10)</P>
<P>#12 (#5 AND #8 AND #11)</P>
<P/>
<P>4 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Antifibrinolytic Agents/</P>
<P>2. exp Aminocaproic Acids/</P>
<P>3. exp Tranexamic Acid/</P>
<P>4. (antifibrinolytic amino acid* or aminocaproic acid* or tranexamic acid*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>5. 1 or 2 or 3 or 4</P>
<P>6. exp Blood Coagulation Disorders/</P>
<P>7. acquired coagulation disorder*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>8. 6 or 7</P>
<P>9. exp Liver Diseases/</P>
<P>10. liver disease*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>11. 9 or 10</P>
<P>12. 5 and 8 and 11</P>
<P>13. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>14. 12 and 13</P>
<P/>
<P>11 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp antifibrinolytic agent/</P>
<P>2. (antifibrinolytic amino acid* or aminocaproic acid* or tranexamic acid*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>3. 1 or 2</P>
<P>4. exp blood clotting disorder/</P>
<P>5. acquired coagulation disorder*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>6. 4 or 5</P>
<P>7. exp liver disease/</P>
<P>8. liver disease*.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>9. 7 or 8</P>
<P>10. 3 and 6 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>12. 10 and 11</P>
<P/>
<P>100 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index EXPANDED</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#4 #3 AND #2 AND #1</P>
<P>#3 TS=("liver disease*")</P>
<P>#2 TS=("acquired coagulation disorder*")</P>
<P>#1 TS=("antifibrinolytic amino acid*" or "aminocaproic acid*" or "tranexamic acid*")</P>
<P/>
<P>2 hits for this update.<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(1) Antifibrinolíticos<BR/>(2) Ensayos clínicos (LILACS filter)</P>
<P>(3) upper gastrointestinal</P>
<P>(4) liver disease<BR/>
</P>
<P>(5) 1 AND 2 AND 3 AND 4</P>
<P/>
<P>0 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>World Health Organization Clinical Trials Search Portal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>antifibrinolytic agent AND gastrointestinal bleeding AND liver disease</P>
<P/>
<P>0 hits for this update.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>metaRegister of Controlled Trials (mRCT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>27 February 2015.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>antifibrinolytic agent AND gastrointestinal bleeding AND liver disease</P>
<P/>
<P>0 hits for this update.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;0 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1 full-text article assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;130 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;130 records after duplicates removed&lt;br&gt;&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;239 records identified through database searching&lt;br&gt;&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;129 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 full-text article excluded (clinical guidelines)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>